Apogee Therapeutics (APGE) Stock Price, News & Analysis

Company Overview

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis. Apogee is advancing a pipeline of additional RORγt-focused programs with potential applications across dermatology and immunology, including conditions such as alopecia areata and lichen planus. Preclinical studies have demonstrated target engagement and a favorable safety profile, supporting the company’s approach to address high-unmet needs in T cell-mediated disease.

Headquartered in the United States, Apogee has established research and development operations to support medicinal chemistry, translational biology and clinical trial execution. The company collaborates with academic centers and contract research organizations to conduct multi-center studies in North America and Europe, generating data to inform regulatory strategy and future growth.

Apogee’s management team brings together experienced leaders in immunology, drug discovery and clinical development. Drawing on a track record of advancing small molecule candidates through regulatory review, the leadership group is focused on driving its RORγt platform toward clinical proof-of-concept and preparing for potential partnerships or collaborations to expand the company’s reach in inflammatory and autoimmune therapeutics.

Key Stats

• Today's Range: $83.39 to $85.03
• 50-Day Range: $66.04 to $92.20
• 52-Week Range: $34.34 to $95.32
• Volume: 413,676 shs
• Average Volume: 623,688 shs
• Market Capitalization: $5.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $112.73
• Consensus Rating: Moderate Buy

Apogee Therapeutics Stock Analysis - MarketRank™

Apogee Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 345th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Apogee Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 2 strong buy ratings, 11 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Apogee Therapeutics has a consensus price target of $112.73, representing about 33.3% upside from its current price of $84.54.

Amount of Analyst Coverage

Apogee Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Apogee Therapeutics are expected to decrease in the coming year, from ($4.57) to ($5.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Apogee Therapeutics is -20.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Apogee Therapeutics is -20.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Apogee Therapeutics has a P/B Ratio of 6.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.06% of the float of Apogee Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Apogee Therapeutics has a short interest ratio ("days to cover") of 15.53, which indicates bearish sentiment.

Change versus previous month

Short interest in Apogee Therapeutics has recently decreased by 1.66%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apogee Therapeutics does not currently pay a dividend.

Dividend Growth

Apogee Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.90

News Sentiment

Apogee Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Apogee Therapeutics this week, compared to 4 articles on an average week.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,271,650.00 in company stock.

Percentage Held by Insiders

24.30% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

APGE Stock Analysis - Frequently Asked Questions

How have APGE shares performed this year?

Apogee Therapeutics' stock was trading at $75.48 at the beginning of the year. Since then, APGE stock has increased by 12.0% and is now trading at $84.54.

How were Apogee Therapeutics' earnings last quarter?

Apogee Therapeutics Inc. (NASDAQ:APGE) announced its earnings results on Monday, March, 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.05) by $0.02.

When did Apogee Therapeutics IPO?

Apogee Therapeutics (APGE) raised $282 million in an IPO on Thursday, July 13th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share.

Who are Apogee Therapeutics' major shareholders?

Top institutional investors of Apogee Therapeutics include Pictet Asset Management Holding SA (0.38%), Candriam S.C.A. (0.36%), Bank of New York Mellon Corp (0.20%) and Fifth Third Bancorp (0.10%). Insiders that own company stock include Nimish P Shah, Michael Thomas Henderson, Fairmount Funds Management Llc, Carl Dambkowski, Jane Henderson and Mark C Mckenna.
View institutional ownership trends.

How do I buy shares of Apogee Therapeutics?

Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Apogee Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Apogee Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 3/02/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APGE
• CIK: 1974640
• Web: www.apogeetherapeutics.com
• Phone: 650-394-5230
• Fax: N/A
• Employees: 91
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Apogee Therapeutics: $112.73
• High Price Target: $160.00
• Low Price Target: $82.00
• Potential Upside/Downside: +33.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$255.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -36.77%
• Return on Assets: -34.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.57
• Quick Ratio: 26.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.23 per share
• Price / Book: 6.39

Miscellaneous

• Outstanding Shares: 61,850,000
• Free Float: 46,823,000
• Market Cap: $5.23 billion
• Optionable: Optionable
• Beta: 0.69